EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PSA): 52-WEEK RESULTS FROM KEEPSAKE 2

被引：0
|
作者：
Ostor, A. [1 ]
Van den Bosch, F. [2 ]
Papp, K. [3 ]
Asnal, C. [4 ]
Blanco, R. [5 ]
Aelion, J. [6 ]
Lu, W. [7 ]
Wang, Z. [7 ]
Soliman, A. M. [7 ]
Eldred, A. [7 ]
Padilla, B. [7 ]
Kivitz, A. [8 ]
机构：
[1] Monash Univ, Cabrini Hosp, Melbourne, Vic, Australia
[2] Univ Ghent, Dept Rheumatol, Ghent, Belgium
[3] K Papp Clin Res, Prob Med Res, Waterloo, ON, Canada
[4] DOM Ctr, Reumatol, Buenos Aires, DF, Argentina
[5] Hosp Univ Marques de Valdecilla, IDIVAL, Santander, Spain
[6] West Tennessee Res Inst, Arthrit Clin, Jackson, TN USA
[7] AbbVie Inc, Immunol, N Chicago, IL USA
[8] Altoona Ctr, Clin Res, Duncansville, PA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.1673
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS1036
引用
收藏
页码：832 / 832
页数：1
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PSA): 52-WEEK RESULTS FROM KEEPSAKE 1
    Kristensen, L. E.
    Keiserman, M.
    Papp, K.
    Mccasland, L.
    White, D.
    Lu, W.
    Soliman, A. M.
    Eldred, A.
    Barcomb, L.
    Behrens, F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 823 - 824
  • [2] Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study
    Ostor, Andrew
    van den Bosch, Filip
    Papp, Kim
    Asnal, Cecilia
    Blanco, Ricardo
    Aelion, Jacob
    Lu, Wenjing
    Wang, Zailong
    Soliman, Ahmed M.
    Eldred, Ann
    Padilla, Byron
    Kivitz, Alan
    [J]. RHEUMATOLOGY, 2023, 62 (06) : 2122 - 2129
  • [3] Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study
    Kristensen, Lars Erik
    Keiserman, Mauro
    Papp, Kim
    McCasland, Leslie
    White, Douglas
    Lu, Wenjing
    Soliman, Ahmed M.
    Eldred, Ann
    Barcomb, Lisa
    Behrens, Frank
    [J]. RHEUMATOLOGY, 2023, 62 (06) : 2113 - 2121
  • [4] Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Trials
    Erik, Lars
    Papp, Kim
    White, Douglas
    Asnal, Cecilia
    Lu, Wenjing
    Soliman, Ahmed
    Padilla, Byron
    Chen, Michael
    Ostor, Andrew
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4255 - 4258
  • [5] Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial
    Ostor, Andrew
    van den Bosch, Filip
    Papp, Kim
    Asnal, Cecilia
    Blanco, Ricardo
    Aelion, Jacob
    Carter, Kyle
    Stakias, Vassilis
    Lippe, Ralph
    Drogaris, Leonidas
    Soliman, Ahmed M.
    Chen, Michael M.
    Padilla, Byron
    Kivitz, Alan
    [J]. RHEUMATOLOGY AND THERAPY, 2024, 11 (03) : 633 - 648
  • [6] Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial
    Ostor, Andrew
    van den Bosch, Filip
    Papp, Kim
    Asnal, Cecilia
    Blanco, Ricardo
    Aelion, Jacob
    Carter, Kyle
    Stakias, Vassilis
    Lippe, Ralph
    Drogaris, Leonidas
    Soliman, Ahmed M.
    Chen, Michael M.
    Padilla, Byron
    Kivitz, Alan
    [J]. RHEUMATOLOGY AND THERAPY, 2024, 11 (03) : 633 - 648
  • [7] Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 2 Trial
    Ostor, Andrew
    Van den Bosch, Filip
    Papp, Kim A.
    Asnal, Cecilia
    Blanco, Ricardo
    Aelion, Jacob
    Stakias, Vassilis
    Iyile, Thomas
    Carter, Kyle
    Soliman, Ahmed
    Drogaris, Leonidas
    Chen, Michael
    Padilla, Byron
    Kivitz, Alan
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2823 - 2826
  • [8] Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial
    Kristensen, Lars Erik
    Keiserman, Mauro
    Papp, Kim
    Mccasland, Leslie
    White, Douglas
    Carter, Kyle
    Lippe, Ralph
    Photowala, Huzefa
    Drogaris, Leonidas
    Soliman, Ahmed M.
    Chen, Michael
    Padilla, Byron
    Behrens, Frank
    [J]. RHEUMATOLOGY AND THERAPY, 2024, 11 (03) : 617 - 632
  • [9] Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
    Ostor, Andrew
    Van den Bosch, Filip
    Papp, Kim
    Asnal, Cecilia
    Blanco, Ricardo
    Aelion, Jacob
    Alperovich, Gabriela
    Lu, Wenjing
    Wang, Zailong
    Soliman, Ahmed M.
    Eldred, Ann
    Barcomb, Lisa
    Kivitz, Alan
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (03) : 351 - 358
  • [10] Risankizumab (RZB) for active psoriatic arthritis (PsA): Integrated subgroup analysis from 2 double-blind, placebo-controlled, phase 3 studies (KEEPsAKE 1 and KEEPsAKE 2)
    Merola, J.
    Duffin, K.
    Padilla, B.
    Xue, Z.
    Photowala, H.
    Kaplan, B.
    McInnes, I.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : S50 - S50
12345